-
Media ReleaseNovartis teams up with actress, producer and activist Eva Longoria to launch Kiss This 4 MBC™ to generate research funding and support for the metastatic breast cancer community
-
Media ReleaseNovartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data
-
Media ReleaseMultimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
-
Media ReleaseNovartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day
-
Media ReleaseNovartis drug Promacta® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
-
Media ReleaseAlcon DAILIES® teams up with US Olympians - world-class gymnast Laurie Hernandez and soccer star Tobin Heath - to launch the Invisible Edge campaign
-
Media ReleaseNovartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
-
Media ReleaseNovartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
-
Media ReleaseNovartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a
-
Media ReleaseNovartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
-
Media ReleaseNovartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
-
Media ReleaseNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness